Table 1.

Comparative studies evaluating PCC and plasma for reversal of warfarin-associated major bleeding

Comparative studies evaluating PCC and plasma for reversal of warfarin-associated major bleeding
Comparative studies evaluating PCC and plasma for reversal of warfarin-associated major bleeding
Comparative studies evaluating PCC and plasma for reversal of warfarin-associated major bleeding
Comparative studies evaluating PCC and plasma for reversal of warfarin-associated major bleeding

ED indicates emergency department; FIM, functional independence measure; GCS, Glasgow coma score; IHD, ischemic heart disease; LOS, length of stay; NR, not reported; PRBC, packed RBCs; rFVIIa, recombinant factor VIIa; RLS, reaction level scale; RR, relative risk; SD, standard deviation; TE, thromboembolic; VK, vitamin K; VTE, venous thromboembolism.

* p ≤ 0.05, statistically significant.

** 4-Factor PCC was superior to plasma.

In the no-PCC group, 16 of 18 patients received FFP.

†† In the no-PCC group, 29 of 39 patients received FFP.

Thirteen patients received 3-factor PCC plus factor VII concentrate, and 16 patients received 4-factor PCC.

Close Modal

or Create an Account

Close Modal
Close Modal